Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VX-702 · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| VX-702 | DRUG | - |
Inclusion Criteria: * Adult patients 18 to 75 years of age with active RA * Must have been taking MTX for at least 6 months * No concurrent DMARD treatment (other than a stable dose of MTX) Exclusion Criteria: * Planned major surgery (e.g., joint replacement) within the duration of the treatment ...
Top 20 of 28 competitors
VX-702 is an investigational small molecule being developed for rheumatoid arthritis. It is a p38 MAP kinase inhibitor studied in Phase 2 clinical trials. The drug is not approved and remains in clinical development.
VX-702 targets p38 MAP kinase, an enzyme involved in inflammatory signaling. By inhibiting this target, the drug is intended to modulate the inflammatory response in rheumatoid arthritis.
VX-702 is being developed by Vertex Pharmaceuticals Incorporated, a biopharmaceutical company traded on NASDAQ under the ticker VRTX.
VX-702 is in Phase 2 clinical development. Two Phase 2 trials have been completed, and the drug is not yet approved by regulatory authorities.
VX-702 has been studied in two completed Phase 2 trials: NCT00205478 with 300 participants and NCT00395577 with 120 participants, both in rheumatoid arthritis. These trials were conducted in multiple European countries.
VX-702 is also known by its chemical name as a p38 MAP kinase inhibitor. No alternative brand names have been disclosed for this investigational compound.